The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
 
Amit Mahipal
Honoraria - Eisai
Consulting or Advisory Role - QED Therapeutics
Research Funding - Taiho Pharmaceutical
 
Xin Gao
Consulting or Advisory Role - Dendreon; Exelixis
Research Funding - Aprea Therapeutics (Inst); Arvinas (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Pfizer (Inst); Takeda (Inst)
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology; Syros Pharmaceuticals; Zentalis
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology
 
Jason S. Starr
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Ipsen; Natera; Pfizer
Research Funding - Incyte (Inst); Macrogenics (Inst); Merus (Inst); Molecular Templates (Inst); Natera; Rafael Pharmaceuticals (Inst); Vedanta Biosciences (Inst)
 
Parminder Singh
Consulting or Advisory Role - Bayer; Genentech/Roche; Janssen Oncology; Pfizer; Prometheus; Seattle Genetics/Astellas (Inst)
Research Funding - EMD Serono (Inst)
 
Muhammad Furqan
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; Jazz Pharmaceuticals
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Biothera (Inst); Celgene (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Afzal Ahrorov
No Relationships to Disclose
 
Denice Hickman
Employment - Aprea Therapeutics
Stock and Other Ownership Interests - Aprea Therapeutics
 
Amy Gubits
Employment - Aprea Therapeutics
Stock and Other Ownership Interests - Aprea Therapeutics
 
Eyal C. Attar
Employment - Agios; Aprea AB
Leadership - Aprea AB
Stock and Other Ownership Interests - Agios; Aprea AB
Consulting or Advisory Role - Teladoc
Travel, Accommodations, Expenses - Agios; Aprea AB
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Archer; ARIAD; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Panasonic; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Satya Das
Honoraria - Medsphere
Speakers' Bureau - Ipsen
Research Funding - Exelixis
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences